Association of early steroid withdrawal with kidney transplant outcomes in first-transplant and retransplant recipients.

IF 4.8 2区 医学 Q1 TRANSPLANTATION
Sunjae Bae, Yusi Chen, Shaifali Sandal, Krista L Lentine, Mark Schnitzler, Dorry L Segev, Mara A McAdams DeMarco
{"title":"Association of early steroid withdrawal with kidney transplant outcomes in first-transplant and retransplant recipients.","authors":"Sunjae Bae, Yusi Chen, Shaifali Sandal, Krista L Lentine, Mark Schnitzler, Dorry L Segev, Mara A McAdams DeMarco","doi":"10.1093/ndt/gfae218","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and hypothesis: </strong>Early steroid withdrawal (ESW) is often preferred over conventional steroid maintenance (CSM) therapy for kidney transplant recipients with low immunological risks because it may minimize immunosuppression-related adverse events while achieving similar transplant outcomes. However, the risk-benefit balance of ESW could be less favorable in retransplant recipients given their unique immunological risk profile. We hypothesized that the association of ESW with transplant outcomes would differ between first-transplant and retransplant recipients.</p><p><strong>Methods: </strong>To assess whether the impact of ESW differs between first and retransplant recipients, we studied 210 086 adult deceased-donor kidney transplant recipients using the Scientific Registry of Transplant Recipients. Recipients who discontinued maintenance steroids before discharge from transplant admission were classified with ESW; all others were classified with CSM. We quantified the association of ESW (vs. CSM) with acute rejection, death-censored graft failure, and death, addressing retransplant as an effect modifier, using logistic/Cox regression with inverse probability weights to control for confounders.</p><p><strong>Results: </strong>In our cohort, 26 248 (12%) were retransplant recipients. ESW was used in 30% of first-transplant and 20% of retransplant recipients. Among first-transplant recipients, ESW was associated with no significant difference in acute rejection (aOR = 1.04 [95% CI = 1.00-1.09]), slightly higher hazard of graft failure (HR = 1.09 [95% CI = 1.05-1.12]), and slightly lower mortality (HR = 0.93 [95% CI = 0.91-0.95]) compared to CSM. Nonetheless, among retransplant recipients, ESW was associated with notably higher risk of acute rejection (OR = 1.42 [95% CI = 1.29-1.57]; interaction p < 0.001) and graft failure (HR = 1.24 [95% CI = 1.14-1.34]; interaction p = 0.003), and similar mortality (HR = 1.01 [95% CI = 0.94-1.08]; interaction p = 0.04).</p><p><strong>Conclusions: </strong>In retransplant recipients, the negative impacts of ESW on transplant outcomes appear to be non-negligible. A more conservatively tailored approach to ESW might be necessary for retransplant recipients.</p>","PeriodicalId":19078,"journal":{"name":"Nephrology Dialysis Transplantation","volume":" ","pages":""},"PeriodicalIF":4.8000,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nephrology Dialysis Transplantation","FirstCategoryId":"88","ListUrlMain":"https://doi.org/10.1093/ndt/gfae218","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"TRANSPLANTATION","Score":null,"Total":0}
引用次数: 0

Abstract

Background and hypothesis: Early steroid withdrawal (ESW) is often preferred over conventional steroid maintenance (CSM) therapy for kidney transplant recipients with low immunological risks because it may minimize immunosuppression-related adverse events while achieving similar transplant outcomes. However, the risk-benefit balance of ESW could be less favorable in retransplant recipients given their unique immunological risk profile. We hypothesized that the association of ESW with transplant outcomes would differ between first-transplant and retransplant recipients.

Methods: To assess whether the impact of ESW differs between first and retransplant recipients, we studied 210 086 adult deceased-donor kidney transplant recipients using the Scientific Registry of Transplant Recipients. Recipients who discontinued maintenance steroids before discharge from transplant admission were classified with ESW; all others were classified with CSM. We quantified the association of ESW (vs. CSM) with acute rejection, death-censored graft failure, and death, addressing retransplant as an effect modifier, using logistic/Cox regression with inverse probability weights to control for confounders.

Results: In our cohort, 26 248 (12%) were retransplant recipients. ESW was used in 30% of first-transplant and 20% of retransplant recipients. Among first-transplant recipients, ESW was associated with no significant difference in acute rejection (aOR = 1.04 [95% CI = 1.00-1.09]), slightly higher hazard of graft failure (HR = 1.09 [95% CI = 1.05-1.12]), and slightly lower mortality (HR = 0.93 [95% CI = 0.91-0.95]) compared to CSM. Nonetheless, among retransplant recipients, ESW was associated with notably higher risk of acute rejection (OR = 1.42 [95% CI = 1.29-1.57]; interaction p < 0.001) and graft failure (HR = 1.24 [95% CI = 1.14-1.34]; interaction p = 0.003), and similar mortality (HR = 1.01 [95% CI = 0.94-1.08]; interaction p = 0.04).

Conclusions: In retransplant recipients, the negative impacts of ESW on transplant outcomes appear to be non-negligible. A more conservatively tailored approach to ESW might be necessary for retransplant recipients.

首次肾移植和再次肾移植受者早期停用类固醇与肾移植结果的关系。
背景和假设:对于免疫风险较低的肾移植受者,早期类固醇停药(ESW)通常比常规类固醇维持治疗(CSM)更受青睐,因为它可以最大限度地减少免疫抑制相关不良事件,同时获得相似的移植结果。然而,考虑到再移植受者独特的免疫风险特征,ESW 的风险-效益平衡可能对他们不那么有利。我们假设 ESW 与移植结果的关系在首次移植和再次移植受者之间会有所不同:为了评估 ESW 对初次移植和再次移植受者的影响是否存在差异,我们利用移植受者科学登记系统研究了 210 086 名成年死体肾移植受者。在移植入院出院前停止维持类固醇治疗的受者被归类为 ESW;所有其他受者被归类为 CSM。我们使用反概率加权的逻辑/Cox回归控制混杂因素,量化了ESW(与CSM相比)与急性排斥反应、死亡校正移植物失败和死亡的关系,并将再次移植作为影响调节因素:在我们的队列中,有26 248人(12%)接受了再次移植。30%的首次移植受者和20%的再次移植受者使用了ESW。在首次移植受者中,ESW与CSM相比,急性排斥反应无显著差异(aOR = 1.04 [95% CI = 1.00-1.09]),移植物失败的风险略高(HR = 1.09 [95% CI = 1.05-1.12]),死亡率略低(HR = 0.93 [95% CI = 0.91-0.95])。尽管如此,在再移植受者中,ESW与急性排斥反应风险显著升高相关(OR = 1.42 [95% CI = 1.29-1.57];交互作用 p 结论:ESW与急性排斥反应风险显著升高相关(OR = 1.42 [95% CI = 1.29-1.57];交互作用 p):在再移植受者中,ESW对移植结果的负面影响似乎不可忽视。对于再移植受者来说,可能需要对 ESW 采取更加保守的方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Nephrology Dialysis Transplantation
Nephrology Dialysis Transplantation 医学-泌尿学与肾脏学
CiteScore
10.10
自引率
4.90%
发文量
1431
审稿时长
1.7 months
期刊介绍: Nephrology Dialysis Transplantation (ndt) is the leading nephrology journal in Europe and renowned worldwide, devoted to original clinical and laboratory research in nephrology, dialysis and transplantation. ndt is an official journal of the [ERA-EDTA](http://www.era-edta.org/) (European Renal Association-European Dialysis and Transplant Association). Published monthly, the journal provides an essential resource for researchers and clinicians throughout the world. All research articles in this journal have undergone peer review. Print ISSN: 0931-0509.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信